Effect of Beta-Blockade on Mortality in Patients With Heart Failure: A Meta-Analysis of Randomized Clinical Trials
Journal of the American College of CardiologyPublished 1 July 1997Open access
Paul A. Heidenreich, Tina T. Lee, Barry M. Massie
Citations363
SJR quartileQ1
SJR score9.02
SNIP6.30
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Pooled evidence suggests that beta-blockade reduces all-cause mortality in patients with CHF and additional trials are required to determine whether carvedilol differs in its effect from other agents.
Abstract
Pooled evidence suggests that beta-blockade reduces all-cause mortality in patients with CHF. Additional trials are required to determine whether carvedilol differs in its effect from other agents.
Keywords
Medicine
Controlled Clinical TrialsMeta-analysis in clinical trials
39,316 Citations1986Rebecca DerSimonian, Nan M. Laird
This paper examines eight published reviews each reporting results from several related trials in order to evaluate the efficacy of a certain treatment for a specified medical condition and suggests a simple noniterative procedure for characterizing the distribution of treatment effects in a series of studies.
JNCI Journal of the National Cancer InstituteStatistical Aspects of the Analysis of Data From Retrospective Studies of Disease
14,860 Citations1959Nathan Mantel, William Haenszel
Journal of Educational StatisticsStatistical Methods for Meta-Analysis
10,479 Citations1988Stanley Wasserman, Larry V. Hedges +1 more
New England Journal of MedicineEffect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction
5,925 Citations1992Marc A. Pfeffer, Eugene Braunwald +16 more
In patients with asymptomatic left ventricular dysfunction after myocardial infarction, long-term administration of captopril was associated with an improvement in survival and reduced morbidity and mortality due to major cardiovascular events.
New England Journal of MedicineEffects of Enalapril on Mortality in Severe Congestive Heart Failure
5,077 Citations1987The Consensus Trial Study Group*
It is concluded that the addition of enalapril to conventional therapy in patients with severe congestive heart failure can reduce mortality and improve symptoms and a significant improvement in NYHA classification was observed in the enAlapril group.
New England Journal of MedicineThe Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
4,656 Citations1996Milton Packer, Michael R. Bristow +5 more
Carvedilol reduces the risk or death as well as the risk of hospitalization for cardiovascular causes in patients with heart failure who are receiving treatment with digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor.
The American Journal of CardiologyEffects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
3,778 Citations1988Karl Swedberg, John Kjekshus
The addition of enalapril to conventional therapy in patients with severe congestive heart failure can reduce mortality and improve symptoms, and the effect seems to be due to a reduction in death from progression of heart failure.
New England Journal of MedicineThe Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure
2,968 Citations1997The Digitalis Investigation Group
Digoxin did not reduce overall mortality, but it reduced the rate of hospitalization both overall and for worsening heart failure, which defines more precisely the role of digoxin in the management of chronic heart failure.
New England Journal of MedicineA Comparison of Enalapril with Hydralazine–Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure
2,836 Citations1991Jay N. Cohn, Gary R. Johnson +17 more
The different effects of the two regimens (enalapril and hydralazine-isosorbide dinitrate) on mortality and physiologic end points suggest that the profile of effects might be enhanced if the regimens were used in combination.
Journal of the American Statistical AssociationChi-Square Tests with One Degree of Freedom; Extensions of the Mantel-Haenszel Procedure
2,627 Citations1963Nathan Mantel
Extensions of application include comparisons of age-adjusted death rates, life-table analyses, comparisons of two sets of quantal dosage-response data, and miscellaneous laboratory applications as appropriate.
Elsevier eBooksStatistical Methods for Meta-Analysis
2,526 Citations1985
The aim of this paper is to introduce several widely-used statistical methods of Meta-analysis, applied generally in medical literatures.
New England Journal of MedicineEffect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure
2,413 Citations1986Jay N. Cohn, Donald Archibald +16 more
The data suggest that the addition of hydralazine and isosorbide dinitrate to the therapeutic regimen of digoxin and diuretics in patients with chronic congestive heart failure can have a favorable effect on left ventricular function and mortality.
CirculationCarvedilol Produces Dose-Related Improvements in Left Ventricular Function and Survival in Subjects With Chronic Heart Failure
1,306 Citations1996Michael R. Bristow, Edward M. Gilbert +10 more
In subjects with mild to moderate heart failure from systolic dysfunction, carvedilol produced dose-related improvements in LV function and dose- related reductions in mortality and hospitalization rate and was generally well tolerated.
The LancetBeneficial effects of metoprolol in idiopathic dilated cardiomyopathy
1,234 Citations1993Finn Waagstein, Åke Hjalmarson +8 more
In patients with idiopathic dilated cardiomyopathy, treatment with metoprolol prevented clinical deterioration, improved symptoms and cardiac function, and was well tolerated.
New England Journal of MedicineAmiodarone in Patients with Congestive Heart Failure and Asymptomatic Ventricular Arrhythmia
1,233 Citations1995Steven Singh, Ross D. Fletcher +7 more
Although amiodarone was effective in suppressing ventricular arrhythmias and improving ventricular function, it did not reduce the incidence of sudden death or prolong survival among patients with heart failure, except for a trend toward reduced mortality among those with nonischemic cardiomyopathy.
New England Journal of MedicineEffect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart Failure
1,183 Citations1996Milton Packer, Christopher M. O’Connor +10 more
A new calcium-channel blocker, amlodipine, did not increase cardiovascular morbidity or mortality in patients with severe chronic heart failure and the possibility that amlidipine prolongs survival in Patients with nonischemic dilated cardiomyopathy requires further study.
CirculationA randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees.
1,061 Citations1994
These results confirm previous trials evidence that a progressively increasing dose of beta-blocker in severe heart failure confers functional benefit, and suggest that benefit frombeta-blockade therapy was greater for those with nonischemic cardiomyopathy.
Oxford University Press eBooksMeta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis
928 Citations1999Diana B. Petitti
The techniques of meta-analysis, decision analysis and cost-effectiveness analysis play an increasingly important role in the formulation of clinical practice guidelines and in decisions about health policy and financing.
The LancetRandomised trial of low-dose amiodarone in severe congestive heart failure
924 Citations1994H. Doval, DanielR Nul +4 more
Low-dose amiodarone proved to be an effective and reliable treatment, reducing mortality and hospital admission in patients with severe heart failure independently of the presence of complex ventricular arrhythmias.
HeartEffect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy.
833 Citations1975Finn Waagstein, Å Hjalmarson +2 more
It is indicated that adrenergic beta-blocking agents can improve heart function in at lease some patients with congestive cardiomyopathy and suggested that increased catecholamine activity may be an important factor for the development of this disease.
CirculationCarvedilol Inhibits Clinical Progression in Patients With Mild Symptoms of Heart Failure
635 Citations1996Wilson S. Colucci, Milton Packer +12 more
Carvedilol, when added to standard therapy, including an ACE inhibitor, reduces clinical progression in patients who are only mildly symptomatic with well-compensated heart failure, and significantly improved several secondary end points.
CirculationDouble-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart Failure
617 Citations1996Milton Packer, Wilson S. Colucci +17 more
These findings indicate that, in addition to its favorable effects on survival, carvedilol produces important clinical benefits in patients with moderate to severe heart failure treated with digoxin, diuretics, and an ACE inhibitor.
The LancetRandomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease
585 Citations1997Australia/New Zealand Heart Failure Research Collaborative Group, -
There was an overall reduction in events resulting in death or hospital admission, and a year of treatment with carvedilol resulted in the avoidance of one such serious event among every 12–13 of these patients with chronic stable heart failure.
Journal of the American College of CardiologyTime course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade
535 Citations1995Shelley Hall, Carlos G. Cigarroa +4 more
Long-term therapy with metoprolol results in a reversal of maladaptive remodeling with reduction in left ventricular volumes, regression ofleft ventricular mass and improved ventricular geometry by 18 months.
New England Journal of MedicineEffects of Vesnarinone on Morbidity and Mortality in Patients with Heart Failure
477 Citations1993Arthur M. Feldman, Michael R. Bristow +9 more
Six months of therapy with 60 mg of vesnarinone per day resulted in lower morbidity and mortality and improved the quality of life of patients with congestive heart failure, however, a higher dose of veNarinone (120 mg per day) increased mortality, suggesting that this drug has a narrow therapeutic range.
CirculationImprovement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial.
440 Citations1985Richard S. Engelmeier, John B. O’Connell +4 more
It is concluded that metoprolol can be given safely to a select group of patients with dilated cardiomyopathy in doses that substantially reduce both resting and exercise heart rates.
Journal of Clinical EpidemiologyMeta-analysis in epidemiology, with special reference to studies of the association between exposure to environmental tobacco smoke and lung cancer: A critique
407 Citations1991Joseph L. Fleiss, Alan J. Gross
It is demonstrated that hastily or improperly designed meta-analyses can lead to results that may not be scientifically valid, as demonstrated by the 1986 report of the National Research Council concerning exposure to environmental tobacco smoke and the risk of lung cancer.
CirculationDouble-Blind, Placebo-Controlled Study of the Long-term Efficacy of Carvedilol in Patients With Severe Chronic Heart Failure
375 Citations1995Henry Krum, Jonathan Sackner‐Bernstein +12 more
Compared with the placebo group, patients in the carvedilol group showed improved cardiac performance, as reflected by an increase in left ventricular ejection fraction and stroke volume index and a decrease in pulmonary wedge pressure, mean right atrial pressure, and systemic vascular resistance.
Journal of the American College of CardiologyCarvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study
374 Citations1995Stephanie L. Olsen, Edward M. Gilbert +4 more
Long-term carvedilol therapy improves rest cardiac function and lessens symptoms in patients with heart failure and resulted in a significant reduction in heart rate and mean pulmonary artery and pulmonary capillary wedge pressures and a significant increase in stroke volume and left ventricular stroke work.
American Journal of EpidemiologyA GENERAL ESTIMATOR FOR THE VARIANCE OF THE MANTEL HAENSZEL ODDS RATIO
330 Citations1986James M. Robins, Sander Greenland +1 more
This commentary presents a new estiof matching variables, unmatched varimator of the variance of the natural log of ables, or both, and encompasses the Mantel-Haenszel odds ratio and illusthe full spectrum of matched and untrates its application in typical case-control matched designs.
Journal of the American College of CardiologyEffects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy
322 Citations1994Marco Metra, Matilde Nardi +2 more
Short-term carvedilol administration reduces heart rate and mean pulmonary artery and pulmonary wedge pressures, whereas it improves both long-term rest and exercise left ventricular systolic function, reduces heart failure symptoms and improves submaximal exercise tolerance in patients with idiopathic cardiomyopathy.
Journal of the American College of CardiologyEffect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: A randomized, double-blind, placebo-controlled study
307 Citations1994Eric J. Eichhorn, Christian M. Heesch +7 more
Beta-adrenergic blocking agents, such as metoprolol, are hemodynamically and energetically beneficial in the treatment of myocardial failure and favorably alters substrate utilization.
CirculationDose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators.
274 Citations1994Michael R. Bristow, John B. O’Connell +8 more
In heart failure from systolic dysfunction, beta-blockade with bucindolol produces a dose-related improvement in and prevents deterioration of left ventricular function.
The American Journal of CardiologyA randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy
251 Citations1985Jeffrey L. Anderson, Joan R. Lutz +5 more
Functional evaluation on follow-up (functional class, San Diego questionnaire and exercise time) all tended to favor those receiving BB, and low-dose BB is tolerated in 80% of IDC patients on a long-term basis.
The American Journal of MedicineLong-term β-Blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: A double-blind, randomized study of bucindolol versus placebo
243 Citations1990E.M. Gilbert, J. G. Anderson +8 more
Bucindolol is well tolerated in patients with idiopathic dilated cardiomyopathy and congestive heart failure, and therapy for 3 months is associated with improved resting cardiac function, improved heart failure symptoms, and a reduction in venous norepinephrine concentration.
CirculationBeta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy.
227 Citations1991Susan Woodley, Edward M. Gilbert +8 more
It is concluded that beta-blockade may produce quantitatively different degrees of response in different kinds of heart muscle disease.
CirculationEffect of Amiodarone on Clinical Status and Left Ventricular Function in Patients With Congestive Heart Failure
216 Citations1996Barry M. Massie, Susan G. Fisher +4 more
Although amiodarone therapy resulted in a substantial increase in left ventricular ejection fraction in patients with congestive heart failure, this was not associated with clinical benefit in the population as a whole.
Journal of the American College of CardiologyBeneficial effects of metoprolol in heart failure associated with coronary artery disease: A randomized trial
198 Citations1994Michael L. Fisher, Stephen S. Gottlieb +5 more
Cautious use of titrated metoprolol appears to be safe and beneficial when added to standard heart failure therapy in patients with dilated cardiomyopathy associated with coronary artery disease.
Journal of the American College of CardiologyOral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy
164 Citations1984Philip J. Currie, Michael Kelly +6 more
A double-blind crossover trial was performed to assess the effect of metoprolol in 10 patients with severe dilated cardiomyopathy and no significant differences were found between the patients with and without coronary disease.
Journal of the American College of CardiologyLong-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy
144 Citations1993Thomas Wisenbaugh, Ivor Katz +7 more
Nebivolol improved stroke volume, ejection fraction and left ventricular end-diastolic pressure, not through a measurable reduction in afterload or a lusitropic effect, but by improving systolic contractile performance.
The American Journal of CardiologyEffects of bisoprolol on heart rate variability in heart failure
118 Citations1996Françoise Pousset, Xavier Copie +8 more
Preliminary data indicate that beta blockers improve clinical status in patients with heart failure, but HRV improvement remains to be demonstrated, and bisoprolol induced a significant increase in HRV parameters related to parasympathetic activity in heart failure.
Journal of the American College of CardiologyA double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy
111 Citations1993David Gilligan, Wan Leong Chan +5 more
In patients with mild or moderately symptomatic hypertrophic cardiomyopathy, exercise capacity was not improved by nadolol or verapamil, and individuals were more often impaired by ndolol than with verAPamil.
The American Journal of CardiologyUsefulness of bucindolol in congestive heart failure
109 Citations1990Stewart G. Pollock, John C. Lystash +3 more
It is concluded that bucindolol may be an effective treatment for CHF when administered chronically and that its nonadrenergic vasodilation May be an important feature.
The American Journal of CardiologyDesign of the Beta-Blocker Evaluation Survival Trial (BEST)
107 Citations1995The Best Steering Committee
This manuscript describes a 2,800-patient randomized trial that will definitively determine whether sympathetic nervous system antagonism with a beta blocker prolongs the life of patients with moderate to severe heart failure.
The American Journal of CardiologyComparison of sestamibi single-photon emission computed tomography with positron emission tomography for estimating left ventricular myocarclial viability
106 Citations1995Robert Soufer, Holley M. Dey +2 more
PET can be helpful in detecting myocardial viability in patients suspected of having had MIBI nonviability in the inferior wall, and MIBI underestimates myocardials viability as assessed by PET.
CirculationMedical advances in the treatment of congestive heart failure.
105 Citations1993Paul W. Armstrong, Gordon W. Moe
Based on available evidence, the best contemporary approach to treatment involves the use of ACE inhibitors coupled with diuretic therapy, either continuous or intermittent, to relieve central or peripheral congestion.
American Heart JournalChanges in plasma endothelin-1 levels reflect clinical response to β-blockade in chronic heart failure
93 Citations1996Henry Krum, Anguo Gu +8 more
It is suggested that endothelin-1 accurately reflects functional, hemodynamic, and neurohormonal responses to beta-blocker therapy in patients with congestive heart failure and may be a useful, noninvasive approach to the evaluation of clinical response to drug therapy in these patients.
JAMARationale for Treatment of Patients With Chronic Heart Failure With Adrenergic Blockade
81 Citations1995Jonathan Sackner‐Bernstein
The pathophysiology of the sympathetic nervous system is reviewed as a basis for examining these clinical trials in order to understand the rationale for β-blockade as a treatment for heart failure.
Journal of the American College of CardiologyImproved exercise hemodynamic status in dilated cardiomyopathy after beta-adrenergic blockade treatment
75 Citations1994Bert Andersson, C Hamm +5 more
Metoprolol improved hemodynamic status in patients with dilated cardiomyopathy at rest and had a more pronounced effect during exercise, achieved along with improved or stable myocardial metabolic data.
American Journal of EpidemiologyTESTS FOR HOMOGENEITY OF EFFECT IN AN EPIDEMIOLOGIC INVESTIGATION1
67 Citations1977Nathan Mantel, Charles Brown +1 more
It is advised that tests for homogeneity be conducted with care, and that thought be given to how effects might be made homogeneous rather than to trying to demonstrate the existence of heterogeneity.
HeartEffect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker.
61 Citations1995John E. Sanderson, W Chan +5 more
Both the advantages of vasodilating beta blockers over metoprolol for initial treatment of heart failure and the usefulness of ANF and BNF measurements for the assessment of drug effects in heart failure compared to traditional haemodynamic measurements are confirmed.
American Heart JournalMetabolic and cardiovascular benefits deriving from β-adrenergic blockade in chronic congestive heart failure
58 Citations1992Giuseppe Paolisso, Antonio Gambardella +5 more
The findings confirm the beneficial cardiologic effects of beta-adrenergic blockade in congestive heart failure and demonstrate that metoprolol is also useful for reversing the metabolic damage caused by exaggerated plasma norepinephrine levels.
JAMAMortality From Congestive Heart Failure— United States, 1980-1990
46 Citations1994
Despite declines in death rates for ischemic heart disease and cerebrovascular disease, improvements in detection and treatment of hypertension, and considerable advances in the diagnosis and management of CHF, mortality has increased since 1980.
American Heart JournalEffects of β-blockade with bisoprolol on heart rate variability in advanced heart failure: Analysis of scatterplots of R-R intervals at selected heart rates
35 Citations1996Xavier Copie, Françoise Pousset +4 more
The effect of beta-blockade on heart-rate variability was assessed at different heart rates in 52 patients with heart failure included in the randomized, placebo-controlled, Cardiac Insufficiency Bisoprolol Study (CIBIS), suggesting that beta- blockade increases parasympathetic or decreases sympathetic tone or both in heart failure patients only at the slowest heart rates.
PubMedThe role of beta-adrenergic blocking agents in preventing sudden cardiac death.
25 Citations1992Bertram Pitt
A new opportunity to test the hypothesis that beta-adrenergic blocking agents are useful in preventing sudden cardiac death, especially in patients with a low left ventricular ejection fraction is offered.
The American Journal of CardiologyMeta-analysis of the use of low-dose beta-adrenergic blocking therapy in idiopathic or ischemic dilated cardiomyopathy
18 Citations1996Dawn G. Zarembski, Paul E. Nolan +2 more
Low-dose beta-adrenergic blocking agents are beneficial in the treatment of patients with ischemic or idiopathic cardiomyopathy and appear to improve NYHA functional class and LVEF.
American Heart JournalAngiotensin-converting enzyme inhibitors and β-blockers in long-term treatment of dilated cardiomyopathy
17 Citations1995Vera Regitz‐Zagrosek, Berndt Leuchs +2 more
At the doses used, the effect of the beta-blocker on dilated cardiomyopathy with moderate functional impairment was at least as great as that of the angiotensin-converting enzyme inhibitor.
HeartLeft ventricular function and beta-blockade in chronic ischaemic heart failure. Double-blind, cross-over study of propranolol and penbutolol using non-invasive techniques.
14 Citations1980A Vedin, John Wikstrand +2 more
Eight patients were recruited for the present study by means ofasingle-blind evaluation of the patients' clinical need forcontinued treatment withdigoxin, and the functional class (NYHA) of thepatients had at least one full class while on placebo instead ofdigoxin.
British Journal of Clinical PharmacologyThe influence of beta‐adrenoceptor blockade on left ventricular function.
12 Citations1982B. Hahn, BE Strauer
In comparison to metoprolol, pindolol produced less reduction in resting heart rate, cardiac index and ejection velocity reflecting the intrinsic sympathomimetic activity of the drug.
American Heart JournalAcute hemodynamic effects of pindolol and propranolol in patients with dilated cardiomyopathy: Relevance of intrinsic sympathomimetic activity
5 Citations1988Jeffrey G. Shanes, Christopher J. Wolfkiel +4 more
Compared to propranolol, pindolol caused less of a reduction in heart rate, cardiac output, cardiac index, stroke volume index, and stroke work index and less of an increase in the mean right atrial pressure, mean pulmonary arterial pressure, means pulmonary capillary wedge pressure, left ventricular end-diastolic pressure, and pulmonary vascular resistance; there was a decrease in systemic vascular resistance.
Clinical CardiologyAn evaluation of the safety of the β‐modulator cicloprolol in chronic heart failure
2 Citations1992Giuseppe Cocco, R Alfiero +1 more
Short‐term administration of cicloprolol is safe in moderate heart failure and improved the quality of life and the work capacity of 5 of 12 patients with congestive failure due to ischemic etiology.
PubMed[The effect of gallopamil and propranolol in patients with ischemic cardiopathy and moderate depression of ventricular function].
2 Citations1995E Simarro, Mario A. Rodríguez +8 more
Both gallopamil and propranolol can be used in patients with coronary heart disease and moderately depressed left ventricular ejection fraction and there were no significant differences between each drug and corresponding placebo on either systolic or diastolic function.
PubMed[Acute hemodynamic effects of the vasodilator beta blocker carvedilol in heart failure].
1 Citations1990Arnd B. Buchwald, C. Unterberg +2 more
Results show that in patients with heart failure, an acute vasodilating effect of i.v. carvedilol is not detectable and total peripheral resistance during exercise after carveilol was higher--significantly so in the CAD-group--than after placebo.